GM-CSF


Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Encyclopedia, Wikipedia.
Related to GM-CSF: interleukin, Cytokines, Sargramostim
AcronymDefinition
GM-CSFGranulocyte Macrophage Colony Stimulating Factor
GM-CSFGranulocyte-Macrophage-Macrophage Colony-Stimulating Factor (pharmacology)
GM-CSFAnti-Granulocyte-Monocyte Colony-Stimulating Factor (pharmacology)
References in periodicals archive ?
Following stimulation with antigen the results revealed an induction of TNF-a and GM-CSF production compared to non-stimulated cells (Fig.
Except for GM-CSF, IL-6, macrophage inflammatory protein 1[alpha] (MIP-1[alpha]), and tumor necrosis factor [alpha] (TNF-[alpha[), all adipokines could be detected in both obese patient and control plasma samples (Fig.
GM-CSF mouthwashes have been shown to cause marked alleviation of existing oral mucositis in several studies without detectable systemic accumulation of GM-CSF upon systemic neutrophil count.
(30) Patients with rare pediatric acute myeloid leukemia have been found to have PAP associated with defective leukemic cell expression of the common [[beta].sub.c] chain and a chains of the GM-CSF receptor.
"The GM-CSF molecule attracts immune cells to the vaccine site, where the immune cells encounter pancreas cancer antigens.
Methylcellulose semi-solid media (Stem Cell Technologies, Inc, Vancouver, BC) containing the following growth factors: stem cell factor (50 ng/mL), GM-CSF (10 ng/mL), Interleukin-3 (10 ng/mL), and Erythropoietin (3 U/mL).
Treatment with IL-2 caused a temporary flu-like syndrome, (23) and pain, redness, and swelling were observed in the majority of patients at the sites of GM-CSF injection.
GM-CSF genes promote the production of lymphocytes and doctors hope they would either prevent a recurrence of cancer or slow the spread of the disease.
Researchers know these naturally occurring molecules by many acronyms, including G-CSF, GM-CSF and EPO.
GSK today announced the start of a phase III clinical development programme with otilimab, an investigational anti-granulocyte macrophage colony-stimulating factor (anti GM-CSF) monoclonal antibody, for patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to disease modifying antirheumatic drugs (DMARD) or targeted therapies.
The Company expects the remaining patients to be included in the coming weeks and believes it remains on target for a BLA filing in 2019 under the BTD the Company previously received from the FDA for naxitamab in combination with GM-CSF for the treatment of relapsed/refractory high-risk neuroblastoma.
Biotechnology company United Therapeutics Corporation (NASDAQ:UTHR) reported on Thursday the receipt of the Health Canada's approval for the combination of Unituxin (dinutuximab for injection), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for neuroblastoma.